UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the United States Food and Drug Administration (FDA). Notably, it is the first and only IL-17A and IL-17F inhibitor approved for treating adults with moderate to severe plaque psoriasis.
Learn More About BIMZELX® – Summary of Product Characteristics
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing psoriasis treatment in this IPC-led symposium at ICD 2025 in Rome.
Oruka has joined the International Psoriasis Council as a 2025 Bronze Level Corporate Member, bringing its best-in-class monoclonal antibody therapies to advance psoriasis and psoriatic arthritis research and patient care.
Join IPC in welcoming Alumis Inc. as a 2024 Bronze Level Corporate Member! Discover how Alumis’ innovative research and dedication to patient care support IPC’s global mission to enhance and improve psoriasis treatment.
How can clinicians navigate emotionally complex patient interactions while maintaining empathy and trust? In this article, Mio Nakamura discusses communication approaches that may help strengthen patient relationships in dermatology settings.
Read summaries from the IPC symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting covering disease modification, immune pathways, therapeutic escape, and psoriasis treatment response.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of systemic corticosteroids in psoriasis. He questions whether they contraindicate the treatment of psoriasis, while also covering his personal experience in prescribing them.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids in psoriasis, covering current use, guidelines, and consequences.
Missed the joint symposium hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the American Academy of Dermatology (AAD) Annual Meeting? Select presentations from Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script are now available, covering diagnostic overlap, emerging tools, treatment-related reactions, and practical strategies for managing complex cases across diverse patient populations.
